BRPI0919932A8 - Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína - Google Patents

Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína

Info

Publication number
BRPI0919932A8
BRPI0919932A8 BRPI0919932A BRPI0919932A BRPI0919932A8 BR PI0919932 A8 BRPI0919932 A8 BR PI0919932A8 BR PI0919932 A BRPI0919932 A BR PI0919932A BR PI0919932 A BRPI0919932 A BR PI0919932A BR PI0919932 A8 BRPI0919932 A8 BR PI0919932A8
Authority
BR
Brazil
Prior art keywords
pcl
lysine
carboxy
polypeptides
peptides
Prior art date
Application number
BRPI0919932A
Other languages
English (en)
Inventor
Geierstanger Bernhard
Ou Weijia
E Cellitti Susan
Crossgrove Tiffany
Chiu Hsien-Po
Grunewald Jan
Hao Xueshi
Uno Tetsuo
Original Assignee
Novartis Ag
Irm Llc
Novartis Int Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Irm Llc, Novartis Int Pharmaceutical Ltd filed Critical Novartis Ag
Publication of BRPI0919932A2 publication Critical patent/BRPI0919932A2/pt
Publication of BRPI0919932A8 publication Critical patent/BRPI0919932A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PIRROLINA-CARBÓXI-LISINA GERADA BIOSSINTETICAMENTE,BEM COMO PROCESSO PARA PREPARAR MÉTODO PARA DERIVATIZAR UMA PROTEÍNA. A presente invenção refere-se a uma pirrolino-carbóxi-lisina (PCL), um análogo de pirrolisina, que é um aminoácido natural, biossinteticamente gerado e métodos para gerar biossinteticamente PCL. Também são descritas aqui proteínas, polipeptídeos e peptídeos que possuem PCL incorporada e métodos para incorporar PCL em tais proteínas, poIipeptídeos e peptídeos. Também é descrita aqui a derivatização sítio-específica de proteínas, polipeptídeos e peptídeos que possuem PCL ou pirrolisina incorporada neles. Também é descrita a reticulação de proteínas, polipeptídeos e peptídeos que possuem PCL ou pirrolisina incorporada neles.
BRPI0919932A 2008-10-24 2009-10-23 Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína BRPI0919932A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10843408P 2008-10-24 2008-10-24
PCT/US2009/061954 WO2010048582A1 (en) 2008-10-24 2009-10-23 Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues

Publications (2)

Publication Number Publication Date
BRPI0919932A2 BRPI0919932A2 (pt) 2017-10-24
BRPI0919932A8 true BRPI0919932A8 (pt) 2018-02-06

Family

ID=41479140

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919932A BRPI0919932A8 (pt) 2008-10-24 2009-10-23 Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína

Country Status (12)

Country Link
US (2) US8785151B2 (pt)
EP (1) EP2356092B1 (pt)
JP (1) JP5542832B2 (pt)
KR (2) KR101316159B1 (pt)
CN (1) CN102264697B (pt)
AU (1) AU2009308163B2 (pt)
BR (1) BRPI0919932A8 (pt)
CA (2) CA2742043C (pt)
EA (1) EA021001B1 (pt)
ES (1) ES2477543T3 (pt)
MX (1) MX342677B (pt)
WO (1) WO2010048582A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
AU2012301793A1 (en) * 2011-08-30 2014-03-20 Quanta Biodesign, Ltd. Branched discrette PEG constructs
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
WO2013130913A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
CN103073627B (zh) * 2013-02-22 2014-03-19 哈尔滨工业大学 微波辅助反胶束分离纯化芸豆凝集素的方法
AU2014229999B2 (en) 2013-03-15 2019-09-12 Medimmune Limited Novel nucleic acid molecules
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
US20170021033A1 (en) * 2014-03-12 2017-01-26 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
WO2015200080A1 (en) 2014-06-23 2015-12-30 Novartis Ag Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3218833A2 (en) * 2014-11-14 2017-09-20 D.E. Shaw Research, LLC Suppressing interaction between bonded particles
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017158612A1 (en) * 2016-03-18 2017-09-21 Department Of Biotechnology Multi-functional chemical agents, and the method for protein modification
US10583199B2 (en) * 2016-04-26 2020-03-10 Northwestern University Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN111432843A (zh) 2017-09-05 2020-07-17 转矩医疗股份有限公司 可逆接头及其用途
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN108395474B (zh) * 2018-01-30 2021-02-19 武汉大学 一种可见光诱导吡唑偶联苯丙氨酸类化合物的方法
CN113166204A (zh) * 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
CN112978709A (zh) * 2019-12-12 2021-06-18 中国科学院大连化学物理研究所 一种碳量子点前驱体组合物、一种碳量子点及其制备方法
US20230398224A1 (en) 2020-02-07 2023-12-14 Novartis Ag Targeted plasma protein degradation
CN112147132B (zh) * 2020-09-23 2021-07-09 山东大学 一种光谱型的近红外电化学发光免疫传感器的制备方法
TWI741843B (zh) * 2020-10-20 2021-10-01 新加坡商億恩診斷有限公司 體液蛋白質濃度檢測裝置及其運作方法
CN113582881B (zh) * 2021-07-29 2022-10-11 浙江新码生物医药有限公司 一种非天然氨基酸及其应用、包含其的重组蛋白以及重组蛋白偶联物
KR20240024235A (ko) * 2021-07-29 2024-02-23 노보코덱스 바이오파마슈티컬즈 컴퍼니 리미티드 비천연 아미노산, 및 이의 용도, 이를 함유하는 재조합 단백질, 및 재조합 단백질 컨주게이트
CN113698468B (zh) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其应用
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
CN117417292B (zh) * 2023-02-20 2024-07-12 浙江新码生物医药有限公司 一种含有杂芳基的非天然氨基酸及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7266613B1 (en) 2000-08-09 2007-09-04 Microsoft Corporation Fast dynamic measurement of bandwidth in a TCP network environment
DK2128246T3 (da) 2001-04-19 2014-05-12 Univ California Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar.
US7993872B2 (en) * 2003-06-18 2011-08-09 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
US20060166319A1 (en) * 2004-08-13 2006-07-27 Chan Michael K Charging tRNA with pyrrolysine
US20060183888A1 (en) * 2004-08-13 2006-08-17 Chan Michael K Pyrrolysine synthesis and modification
CA2648009A1 (en) 2006-02-22 2007-09-07 Riken Method for synthesis of suppressor trna, dna construct, and production of protein having non-natural amino acid integrated therein by using the dna construct

Also Published As

Publication number Publication date
CA2871855A1 (en) 2010-04-29
MX2011004246A (es) 2011-07-13
CN102264697B (zh) 2015-09-09
EP2356092A1 (en) 2011-08-17
BRPI0919932A2 (pt) 2017-10-24
US8785151B2 (en) 2014-07-22
KR101316159B1 (ko) 2013-10-15
CA2871855C (en) 2017-08-15
CA2742043A1 (en) 2010-04-29
AU2009308163B2 (en) 2013-01-10
MX342677B (es) 2016-10-07
EA021001B1 (ru) 2015-03-31
EP2356092B1 (en) 2014-04-16
JP5542832B2 (ja) 2014-07-09
WO2010048582A1 (en) 2010-04-29
AU2009308163A1 (en) 2010-04-29
KR20130086386A (ko) 2013-08-01
ES2477543T3 (es) 2014-07-17
US20110262963A1 (en) 2011-10-27
JP2012506869A (ja) 2012-03-22
US9624520B2 (en) 2017-04-18
KR20110089145A (ko) 2011-08-04
CA2742043C (en) 2014-11-25
US20140302553A1 (en) 2014-10-09
EA201100659A1 (ru) 2011-12-30
CN102264697A (zh) 2011-11-30

Similar Documents

Publication Publication Date Title
BRPI0919932A8 (pt) Pirrolina-carbóxi-lisina gerada biossinteticamente, bem como processo para preparar método para derivatizar uma proteína
MX2021005757A (es) Metodos y composiciones para la secuenciacion de proteinas.
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
BRPI0820114A8 (pt) Método de aumentar a sensibilidade de uma fitase derivada de escherichia coli a uma pepsina
BRPI0814220B8 (pt) purificação de fator viii usando uma resina multimodal ou de modo misto
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
ES2668967T3 (es) Inmunógenos de Escherichia coli con solubilidad mejorada
BR112016020517A2 (pt) método de produção de lipídeo através da utilização de ss-cetoacil-acp sintase
PE20170906A1 (es) Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados
BR112018077358A2 (pt) tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
MX2014011600A (es) Proteínas nutritivas, fragmentos y métodos.
BR112021023218A2 (pt) Polipeptídeos sintase de canabinoide otimizados
UY31875A (es) Novedosos genes involucrados en la biosíntesis
BR112012027893A2 (pt) peptídeo para aumento da bioestabilidade de substância bioativa e substância biotiva que possui bioestabilidade aumentada.
MX2017015927A (es) Fragmentos mutantes de proteina ras.
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
BR112022006233A2 (pt) Composições e métodos para síntese in vivo de polipeptídeos não naturais
BR112016011095A2 (pt) Sequência de endolisina el188 modificada
MY187130A (en) Variants of gal2 transporter and their uses
BR112017019202A2 (pt) ss-frutofuranosidase melhorada
BR112016013157A2 (pt) peptídeos resistentes à protease
BR112022014586A2 (pt) Colágeno dietário não derivado de animais

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2485 DE 21-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.